Lactylation first attracted wide attention as a modification of histones, the proteins around which DNA is wound, where it was shown to activate gene expression in response to metabolic cues. More recently, researchers have realized that lactylation also strikes non-histone proteins, potentially rewiring signaling pathways throughout the cell. The new study addresses a key gap in this emerging field: what lactylation actually does to non-histone proteins inside hepatocellular carcinoma, and whether those effects matter for patients. The answer, according to the team, is that lactylation can functionally reprogram a tumor suppressor, converting a molecular brake on cancer into a bystander that no longer applies the brakes effectively.

OVOL2, short for Ovo-like zinc finger 2, is a transcription factor, a DNA-binding protein that controls the activity of target genes. In the liver, it has been associated with restraining epithelial-mesenchymal transition, the cellular program that allows stationary epithelial cells to become invasive and migratory, a hallmark of cancer progression. The researchers began by mining large public datasets from The Cancer Genome Atlas and the Gene Expression Omnibus, and found that OVOL2 messenger RNA is consistently reduced in hepatocellular carcinoma tissues compared with healthy liver tissue. That observation fit the conventional view of OVOL2 as a gene that cancer cells would prefer to silence.

But when the team examined human hepatocellular carcinoma samples and paired adjacent non-tumorous tissues directly, they noticed something paradoxical. Signals associated with OVOL2 lactylation were elevated in the tumor tissues, and higher levels of these lactylation marks correlated with shorter overall survival and increased postoperative recurrence. Notably, however, in multivariate analysis that accounted for other clinical variables, OVOL2 lactylation was not an independent prognostic factor, an important caveat the authors report transparently. The correlation suggests the modification tracks with aggressive disease, even if it does not stand alone as a predictive marker once standard clinical parameters are considered.

To characterize the modification at the molecular level, the researchers deployed a demanding toolkit: immunoprecipitation to pull OVOL2 out of cell extracts, immunoblotting and immunofluorescence to detect and localize the modified protein, immunohistochemistry to map its distribution in tissue sections, and liquid chromatography coupled with tandem mass spectrometry to pinpoint exactly where on the protein the lactyl group lands. The mass spectrometry identified lysine 3, the third amino acid in the OVOL2 protein, as the site of modification. Lysine residues carry positively charged side chains that often participate in critical molecular interactions, so adding a bulky, chemically distinct lactyl group at such a position can profoundly change how a protein behaves.

The enzyme responsible for installing the mark turned out to be KAT8, a lysine acetyltransferase better known for modifying histones. When the team manipulated KAT8 levels, OVOL2 lactylation rose and fell accordingly, establishing KAT8 as the writer of this particular mark. The functional consequences were dramatic. Lactylation at lysine 3 reduced the ability of OVOL2 to accumulate in the nucleus, the compartment where a transcription factor must reside to do its job. Subcellular fractionation experiments confirmed this shift, and the weakened nuclear presence translated into a loss of transcriptional repression at one of OVOL2’s key target genes, TRIM54, which encodes tripartite motif-containing 54, an E3 ubiquitin ligase that tags other proteins for destruction.

With OVOL2’s grip on TRIM54 loosened, TRIM54 levels climbed, and the consequences cascaded further down the chain. The study shows that elevated TRIM54 promotes K48-linked ubiquitination of RBM47, an RNA-binding protein whose abbreviation stands for RNA-binding motif 47. K48-linked ubiquitin chains are the canonical signal that directs a protein to the proteasome, the cell’s garbage disposal complex, for degradation. In other words, the pathway reads like a molecular relay: lactate accumulation leads to KAT8-mediated lactylation of OVOL2 at lysine 3, which weakens the tumor suppressor’s nuclear function, which lifts repression of TRIM54, which destroys RBM47, and which ultimately facilitates hepatocellular carcinoma growth. Each link in that chain was tested with gain- and loss-of-function assays, reporter assays, chromatin immunoprecipitation and CUT&Tag, a technique called cleavage under targets and tagmentation that maps where a protein binds across the genome.

Perhaps the most clinically provocative part of the study is the therapeutic proof of concept. The researchers designed a cell-penetrating peptide, a short amino acid chain that can cross cellular membranes, aimed at reducing OVOL2 lactylation. When evaluated in cell line-derived xenograft models, in which human cancer cells are implanted into animals, the peptide suppressed tumor growth in vivo. The result suggests that blocking a single lactylation event on a single protein may be enough to restore some tumor-suppressive function, offering a template for drugs that target the lactylation machinery rather than the metabolic pathway as a whole. Cell-penetrating peptides remain an early-stage modality, and the authors are careful to frame this as a potential strategy rather than a ready treatment, but the experiment demonstrates that the pathway is pharmacologically addressable.

The broader significance of the work lies in its reframing of what a tumor suppressor is. Textbook descriptions often treat these proteins as fixed entities whose loss, through mutation or deletion, removes a brake on cell division. This study instead highlights what the authors call post-translational modification-dependent functional plasticity: a tumor suppressor can be present and genetically intact yet functionally neutralized by a chemical tag imposed by the metabolic environment. In tumors such as hepatocellular carcinoma, which arise frequently in the context of metabolic disease and hypoxic, nutrient-stressed tissue, lactate is abundant, and the lactylation landscape is correspondingly rich. A suppressor like OVOL2 can thus be silenced without ever touching its gene.

For patients with hepatocellular carcinoma, one of the deadliest cancers worldwide and one whose incidence continues to climb in parallel with obesity, diabetes and viral hepatitis, the study offers both a mechanistic insight and a cautious note of realism. The clinical data link OVOL2 lactylation to survival and recurrence, but not independently of established prognostic factors, and the therapeutic peptide has so far been tested only in animal models. Still, the identification of a KAT8-OVOL2-TRIM54-RBM47 axis gives researchers a defined set of molecular targets, and it strengthens the case that the metabolic tumor microenvironment communicates with the genome not only through gene expression but through chemical edits to the proteins that read the genome itself. As lactylation research matures, tumors may increasingly be understood as ecosystems in which waste products become weapons, and the next generation of therapies may aim to disarm them at the point of attachment.

Subject of Research: Lactylation of the tumor suppressor OVOL2 in hepatocellular carcinoma progression

Article Title: Lactylation of OVOL2 impairs its tumor-suppressive activity to promote hepatocellular carcinoma growth

Article References: Zhang, Z., Chen, Z., Wu, J., Ye, D., Yao, Y., Wu, H., Zhang, X., Yang, H., Wang, X., & Tang, N. (2026). Lactylation of OVOL2 impairs its tumor-suppressive activity to promote hepatocellular carcinoma growth. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08959-5

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08959-5

Keywords: OVOL2, lactylation, hepatocellular carcinoma, KAT8, TRIM54, RBM47, post-translational modification, tumor suppressor, cancer metabolism, ubiquitination, liver cancer, cell-penetrating peptide

A new study published in the journal Cellular and Molecular Life Sciences offers a striking answer. A team of researchers led by Yulei Wang, Zuhao Liu, Yameng Wang, Zhiyu Xing and Meisheng Ma of the Department of Histology and Embryology at Tongji Medical College, Huazhong University of Science and Technology in Wuhan, China, reports that the assembly of the NSL complex is driven by liquid-liquid phase separation, a physical process increasingly recognized as a central organizing principle of the cell interior. At the heart of the discovery is KANSL1, the essential scaffolding subunit of the complex, which the researchers show can condense into droplet-like compartments that recruit the other components and enable the intact complex to form. The work, published as an open-access article, reframes the NSL complex not as a machine that snaps together through rigid lock-and-key contacts alone, but as one whose architecture emerges from the soft-matter physics of biomolecular condensates.

To appreciate the significance of the finding, it helps to understand what the NSL complex actually is. The complex comprises at least seven evolutionarily conserved subunits: KANSL1, KANSL2, KANSL3, WDR5, MCRS1, KAT8 and PHF20, along with two associated factors, OGT and HCF1. KAT8, also known as MOF, is the catalytic engine, a histone acetyltransferase that deposits acetyl groups on histone proteins, thereby loosening chromatin and permitting gene expression. KANSL1, by contrast, contributes no catalytic activity of its own, but it is indispensable. It holds the complex together structurally and regulates its function, and previous work had established that without KANSL1 the complex cannot maintain its integrity. What remained elusive was the molecular mechanism underlying this regulatory role, and that is precisely the gap the new study set out to fill.

The researchers’ attention focused on a specific segment of the KANSL1 protein: intrinsically disordered region 4, or IDR4, a stretch of amino acids spanning residues 733 to 857 near the protein’s C-terminal end. Intrinsically disordered regions are segments of proteins that do not fold into a fixed three-dimensional structure. Instead, they remain floppy and dynamic, a property long considered puzzling but now understood to be crucial for many regulatory functions. One of the most consequential of these functions is liquid-liquid phase separation, the process by which disordered, multivalent proteins coalesce, like oil droplets in water, into concentrated liquid compartments that exchange molecules with their surroundings. Membrane-less organelles such as nucleoli and stress granules form this way, and growing evidence implicates phase separation in the organization of chromatin and transcriptional machinery.

Demonstrating that KANSL1 undergoes phase separation required the team to show that the protein displays the characteristic behaviors of a liquid condensate. The study reports that KANSL1 undergoes liquid-liquid phase separation mediated by IDR4, meaning that this specific disordered segment is both necessary and sufficient to drive the condensation process. In the condensed state, KANSL1-rich droplets behave as spatial hubs. Rather than assembling through a sequence of pairwise protein-protein interactions at some random location in the nucleus, the complex appears to build itself inside these droplets, where the local concentration of components is dramatically elevated. This spatial assembly mechanism solves a practical problem for the cell: finding and correctly combining nine different subunits in the vast nuclear volume becomes far more efficient when one partner first creates a dedicated reaction vessel.

The functional consequences of this condensation are substantial. According to the study, IDR4-dependent phase separation promotes the recruitment of KANSL2 and KANSL3, two of the complex’s conserved subunits, enabling the assembly of the intact NSL complex. In other words, the droplets act as gathering points that draw in the remaining parts and allow the full machine to take shape. Critically, the researchers found that this phase separation is not merely a structural curiosity. It is essential for the histone acetyltransferase activity of the NSL complex, meaning that without the condensation event, KAT8 cannot efficiently carry out the chemical modification of histones that the complex exists to perform. The physical state of the scaffold directly controls the enzymatic output of the machine it supports.

That enzymatic output, in turn, feeds directly into gene regulation. The NSL complex binds preferentially to the promoters of housekeeping genes, and its acetylation of histones at those sites is a key determinant of their transcriptional activity. The new study demonstrates that KANSL1 phase separation is required for the transcriptional regulation of the complex’s target genes, closing the causal chain from a disordered protein segment, through condensate formation and complex assembly, to enzymatic activity, and finally to the expression levels of genes that sustain cellular life. It is a vivid illustration of what biophysicists have argued for years: that the physical organization of the nucleus, down to the mesoscale behavior of individual proteins, can be as important to gene control as the DNA sequence itself.

The researchers also connected their findings to cellular behavior, showing that KANSL1 phase separation governs the proliferation and migration of HeLa cells, a widely used laboratory cell line derived from cervical cancer tissue. This observation carries particular weight given the established links between NSL complex subunits and oncogenesis. If the phase-separated state of KANSL1 is required for the complex to function, then perturbing that state, whether by mutation, altered expression, or pharmacological interference, could in principle disrupt the transcriptional program that cancer cells rely upon. While the study does not claim a therapeutic application, it identifies a concrete biophysical mechanism that could be targeted in future work on cancers and developmental disorders involving NSL complex dysfunction.

The clinical resonance of KANSL1 extends beyond cancer. The gene encoding KANSL1 lies within the 17q21.31 region, and haploinsufficiency of KANSL1 is known to underlie a neurodevelopmental disorder characterized by intellectual disability and developmental delay, a condition closely associated with what is often called Koolen-de Vries syndrome. The new findings suggest a possible mechanistic lens through which such mutations might act: changes that compromise the phase-separation behavior of IDR4, or the disordered region’s ability to recruit partner subunits, could cripple complex assembly even when the protein is present. Testing that idea in patient-derived systems would be a natural next step, and the study’s identification of a specific residue range, 733 to 857, gives researchers a precise molecular handle for such experiments.

More broadly, the work adds to a rapidly expanding catalog of cellular processes organized by biomolecular condensates, and it does so in a domain where the stakes are especially high. Epigenetic regulators such as the NSL complex sit at the intersection of development, disease and basic cellular physiology, and understanding how they assemble has been a longstanding challenge. By showing that a scaffolding subunit can self-organize the assembly of an entire chromatin-modifying machine through phase separation, the study broadens the mechanistic understanding of how liquid-liquid phase separation contributes to multi-protein complex formation and epigenetic gene regulation. It also raises new questions that the field will now pursue: How is the condensation of KANSL1 regulated in time and space? Do disease mutations alter the material properties of the condensates? And can the droplets be modulated, safely and specifically, to treat the disorders that arise when this essential assembly line falters? For now, the study stands as a compelling demonstration that some of the cell’s most important molecular machines are built not on rigid frames, but on droplets of liquid protein.

Subject of Research: Liquid-liquid phase separation of KANSL1 in the assembly and function of the NSL chromatin-modifying complex

Article Title: KANSL1 condensates drive spatial assembly of NSL complex

Article References: Wang, Y., Liu, Z., Wang, Y., Xing, Z., & Ma, M. (2026). KANSL1 condensates drive spatial assembly of NSL complex. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06453-1

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06453-1

Keywords: KANSL1, NSL complex, liquid-liquid phase separation, chromatin, epigenetics, histone acetyltransferase, KAT8, intrinsically disordered regions, gene regulation, housekeeping genes, biomolecular condensates, transcription

Ferroptosis is an iron-dependent, non-apoptotic form of cell death defined by the catastrophic accumulation of lipid peroxides in cellular membranes. Unlike apoptosis, which cancer cells frequently evade through well-characterized mutations, ferroptosis depends on the lipid composition of the cell, and one enzyme sits at the heart of that dependency: acyl-CoA synthetase long-chain family member 4, commonly abbreviated ACSL4. ACSL4 shapes the membrane pool of oxidizable polyunsaturated fatty acids, and cells with high ACSL4 levels are markedly more vulnerable to ferroptotic death. The new work demonstrates that pancreatic cancer cells actively destroy ACSL4 under hypoxic conditions, and that this destruction is orchestrated by an unexpected player drawn from the machinery of valine, an essential branched-chain amino acid.

The researchers began by comparing tumor samples from patients who responded to gemcitabine-based neoadjuvant chemotherapy with those from non-responders. Metabolomic and transcriptomic profiling revealed that valine, leucine, and isoleucine degradation was significantly enriched in non-responders, and within that pathway the gene encoding MMSDH, ALDH6A1, stood out for its association with poor treatment response and reduced disease-free survival. Transcription factor analysis traced elevated MMSDH expression to SP1, a transcription factor that binds the ALDH6A1 promoter in gemcitabine-resistant tumors, suggesting that the metabolic wiring of these cancers is rewired at the gene expression level before any drug ever enters the cell.

The mechanistic story then deepens in the oxygen-starved interiors of pancreatic tumors. Hypoxia, the researchers found, triggers an enzyme called GCN5 to install a lactyl group, a derivative of lactate, onto MMSDH at the amino acid lysine 113. This modification, known as lactylation, is part of a growing family of metabolite-driven protein modifications that have recently been shown to regulate DNA repair, chromatin biology, and now cancer metabolism. Lactylated MMSDH physically interacts with ACSL4 and, through its catalytic activity, generates propionyl-CoA, a short-chain acyl intermediate of valine catabolism. That propionyl-CoA is then handed to another acetyltransferase, KAT8, which uses it to attach a propionyl group to ACSL4 at lysine 606.

The consequences of this single chemical mark are profound. Propionylation at K606 repositions ACSL4 so that it binds HSC70, the cytosolic chaperone that recognizes the KFERQ-like targeting motifs required for chaperone-mediated autophagy, a selective degradation pathway in which individual proteins are unfolded and threaded into lysosomes. Once flagged in this way, ACSL4 is destroyed, its lipid-remodeling activity collapses, and the tumor cell becomes resistant to the lipid peroxidation that gemcitabine otherwise promotes. Using mass spectrometry, the team confirmed both the K113 lactylation on MMSDH and the K606 propionylation on ACSL4 in hypoxic pancreatic cancer cells, and showed that mutant versions of these proteins that cannot be modified fail to drive ACSL4 degradation or protect cells from ferroptotic death induced by gemcitabine, erastin, or RSL3.

Critically, the findings are not confined to cell culture. In an analysis of patient cohorts, tumors harboring high levels of MMSDH K113 lactylation and ACSL4 K606 propionylation displayed low ACSL4 protein, heightened ferroptosis resistance, and poor clinical response to neoadjuvant chemotherapy. Mouse xenograft experiments extended the picture: tumor cells engineered to express non-modifiable mutants of MMSDH or ACSL4 lost their protective shield and became acutely vulnerable to gemcitabine, while cells bearing the modification-enhancing wild-type enzymes grew aggressively even under low-oxygen conditions and responded poorly to treatment. The team also showed that the same axis operates in lung and ovarian cancer cell lines, hinting that MMSDH-mediated ACSL4 propionylation may be a broader mechanism of ferroptosis evasion across solid tumors.

Perhaps the most translational aspect of the study lies in two therapeutic strategies the authors developed to disrupt this axis. The first is dietary: because MMSDH is a valine catabolism enzyme that depends on valine-derived substrate to generate propionyl-CoA, restricting dietary valine in mice starved the pathway of its fuel. Combining valine-restricted diets with gemcitabine synergistically restored lipid peroxidation and suppressed tumor growth, notably without causing significant toxicity, weight loss, or metabolic distress in the animals. The second approach is pharmacological: the team designed cell-penetrating blocking peptides centered on the lactylated K113 sequence of MMSDH. A lead peptide disrupted the interaction between lactylated MMSDH and ACSL4, prevented ACSL4 propionylation and degradation, restored ferroptotic sensitivity, and markedly potentiated gemcitabine in both subcutaneous and orthotopic pancreatic tumor models while improving animal survival.

Beyond the immediate therapeutic implications, the study expands the conceptual map of how post-translational modifications couple cellular metabolism to cell fate. Amino acid catabolic enzymes are increasingly appreciated as moonlighting regulators of signaling and protein stability, and this work adds a new chapter by showing that a valine-processing enzyme can be co-opted by hypoxia-driven lactylation to flag a ferroptosis gatekeeper for lysosomal destruction. It also illustrates a chemical relay of remarkable economy: hypoxia produces lactate, lactate lactylates MMSDH, lactylated MMSDH produces propionyl-CoA from valine, and propionyl-CoA propionylates ACSL4, linking three metabolic programs, glycolysis, branched-chain amino acid catabolism, and lipid metabolism, into a single survival circuit. The authors’ clinical data suggest that MMSDH K113 lactylation and ACSL4 K606 propionylation may serve as biomarkers for predicting which pancreatic cancer patients will benefit from gemcitabine-based neoadjuvant regimens, potentially guiding treatment selection in a disease where therapeutic options remain painfully limited.

Challenges remain before this biology reaches the clinic. Blocking peptides must be optimized for delivery, stability, and specificity in humans, and dietary valine restriction will need careful evaluation in clinical trials, particularly given the catabolic state of many pancreatic cancer patients. Yet the study provides something pancreatic oncology has long needed: a mechanistically resolved, chemically validated, and clinically correlated explanation for why so many tumors shrug off chemotherapy, together with concrete tools to break that resistance. By exposing the GCN5-MMSDH-ACSL4 axis, the Zhejiang University team has turned a metabolic quirk of hypoxic tumor cells into a target, and in doing so opened a plausible path toward making ferroptosis-inducing chemotherapy a reality for one of medicine’s most intractable cancers.

Subject of Research: Hypoxia-driven MMSDH lactylation and ACSL4 propionylation as a mechanism of ferroptosis evasion and chemotherapy resistance in pancreatic ductal adenocarcinoma

Article Title: MMSDH facilitates ACSL4 propionylation to counteract ferroptosis upon hypoxia and impairs PDAC chemotherapy efficacy

Article References: Zheng, P., Lin, Y., Zhang, M., Tang, Z., Qin, W., Xiao, M., Sun, X., Shen, Y., Hu, Z., Ru, S., Duan, Y., Dong, B., Wen, T., Li, M., Wu, H., Hou, Y., Ji, G., Wang, Z., Wu, X., … Xu, D. (2026). MMSDH facilitates ACSL4 propionylation to counteract ferroptosis upon hypoxia and impairs PDAC chemotherapy efficacy. Nature Cancer. https://doi.org/10.1038/s43018-026-01236-w

Image Credits: AI Generated

DOI: 10.1038/s43018-026-01236-w

Keywords: pancreatic ductal adenocarcinoma, ferroptosis, MMSDH, ACSL4, lactylation, propionylation, hypoxia, gemcitabine resistance, chaperone-mediated autophagy, valine metabolism, GCN5, KAT8